Uveal melanoma

Portfolio Company Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial

Retrieved on: 
星期四, 十二月 21, 2023
Patient, Uveal melanoma, Biotechnology, Compass, Life, Radiation, Safety, LSE, Paratriathlon, Pharmaceutical industry, Online shopping, Aura

LONDON, 8 December 2023: Arix Bioscience plc (“Arix”) (LSE: ARIX), a transatlantic venture capital company focused on investing in breakthrough biotechnology companies, notes that its Core Portfolio company, Aura Biosciences (“Aura”) (NASDAQ: AURA) has announced that the first patient has been dosed in the global Phase 3 CoMpass trial evaluating the safety and efficacy of bel-sar for the first-line treatment of adult patients with early-stage choroidal melanoma.

Key Points: 
  • LONDON, 8 December 2023: Arix Bioscience plc (“Arix”) (LSE: ARIX), a transatlantic venture capital company focused on investing in breakthrough biotechnology companies, notes that its Core Portfolio company, Aura Biosciences (“Aura”) (NASDAQ: AURA) has announced that the first patient has been dosed in the global Phase 3 CoMpass trial evaluating the safety and efficacy of bel-sar for the first-line treatment of adult patients with early-stage choroidal melanoma.
  • Arix holds 1,508,483 shares in Aura.
  • The holding value of these shares will continue to be determined by the market price of Aura’s shares.
  • Robert Lyne, CEO of Arix, commented: “We are pleased to see Aura reach this major milestone and progress into phase 3 trials.

Immatics Announces Third Quarter 2023 Financial Results and Business Update

Retrieved on: 
星期二, 十一月 14, 2023
Senior, Entrepreneurship, CRS, Peptide, Regenerative Medicine Advanced Therapy, Patient, Triple-negative breast cancer, Cell, Research, Pharmacology, Therapy, Conference, ORR, Neurotoxicity, Infrared spectroscopy correlation table, Cytokine release syndrome, Uveal melanoma, Bristol Myers Squibb, Safety, Head, Cancer, Administration, CD4, PRAME, Uterine cancer, Lung cancer, Melanoma, Ovarian cancer, Half-life, Development, SAB, BRAF, CD8, MAGEA4, Cytopenia, TCR, Protein, FDA, DLT, Messenger, Cmax, Toxic epidermal necrolysis, Sarcoma, CMC, Neoplasm, Vaccine, Medical imaging, Pharmaceutical industry, Cryptocurrency, Fine chemical, Drug, Moderna, NSCLC

“Immatics has had a strong quarter and made steady progress both in terms of the advancement of our clinical programs and in business development.

Key Points: 
  • “Immatics has had a strong quarter and made steady progress both in terms of the advancement of our clinical programs and in business development.
  • An update on the clinical development plan is expected in the first quarter of 2024.
  • An update on the clinical development plan is expected in the first quarter of 2024.
  • On September 11, Immatics announced a strategic multi-platform collaboration with Moderna, combining Immatics’ target and TCR platforms with Moderna’s cutting-edge mRNA technology.

Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy PV-10 for Metastatic Uveal Melanoma

Retrieved on: 
星期一, 十一月 13, 2023
Uveal melanoma, Disease, Mum, OTCQB, Liver, Mortality, Patient, CMR, Kaplan–Meier estimator, Nivolumab, Ipilimumab, PET-CT, Springfield Armory M1A, Acceptability, Renewable energy, Pharmaceutical industry, Medical imaging

KNOXVILLE, TN, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today provided updated data from an ongoing Phase 1 clinical trial of investigational cancer immunotherapy PV-10 (rose bengal sodium) for the treatment of uveal melanoma (UM) metastatic to the liver (mUM) ( NCT00986661 ).

Key Points: 
  • KNOXVILLE, TN, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today provided updated data from an ongoing Phase 1 clinical trial of investigational cancer immunotherapy PV-10 (rose bengal sodium) for the treatment of uveal melanoma (UM) metastatic to the liver (mUM) ( NCT00986661 ).
  • mUM patients enrolled in this study received 1 or more cycles of PV-10 injection into 1 or more hepatic metastases.
  • Where indicated, standard of care immune checkpoint blockade (CB), as either monotherapy pembrolizumab or the combination of ipilimumab and nivolumab (IN), was also administered.
  • Dominic Rodrigues, Vice Chair of the Provectus’s Board of Directors, said, “Objective response is uncommon and complete metabolic response is rare in metastatic uveal melanoma.

Turnstone Biologics Corp. Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights

Retrieved on: 
星期五, 十一月 10, 2023
Uveal melanoma, Selection, Colorectal cancer, Investment, Breast cancer, Administration, Patient, Piper Sandler Companies, Melanoma, Immunotherapy, Takeda Oncology, Conference, IPO, SITC, R, Research and development, Coronavirus Scientific Advisory Board, Physician, TIL, Research institute, Pharmaceutical industry, Turnstone

SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today reported financial results for the quarter ended September 30, 2023, and provided recent business highlights.

Key Points: 
  • In October 2023, Turnstone appointed Jeffrey S. Weber, M.D., Ph.D., to its Scientific Advisory Board.
  • In July 2023, Turnstone priced its initial public offering (IPO) at $12.00 per share.
  • Cash, Cash Equivalents and Short-Term Investments: As of September 30, 2023, cash, cash equivalents and short-term investments were $109.1 million.
  • Net Loss: Net loss for the three months ended September 30, 2023, was $17.3 million, compared to net loss of $16.2 million for the third quarter of 2022.

Global CD3 Antibodies Market, Dosage, Price, & Sales Report 2023-2028: $5 Billion Opportunity, Clinical Trials Insights on 250 Antibodies, and 9 Commercially Approved CD3 Antibodies - ResearchAndMarkets.com

Retrieved on: 
星期五, 十二月 15, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Uveal melanoma, Multiple myeloma, Indication, AstraZeneca, EMA, Leukemia, Catumaxomab, CD19, FDA, Acute lymphoblastic leukemia, Regeneron Pharmaceuticals, Cancer, Clinical trial, Muromonab-CD3, Antibody, CD3, Lymphoma, Amgen, Generic drug, Vaccine, Blinatumomab

The "Global CD3 Antibodies Market, Dosage, Price, Sales & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global CD3 Antibodies Market, Dosage, Price, Sales & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering.
  • However, both these CD3 antibodies were withdrawn from the market for different clinical and commercial reasons, but, nevertheless, positioned themselves as pioneers of the CD3 antibodies market.
  • Among these is the global market value of CD3 antibodies, which has been increasing every quarter as new antibodies are approved and introduced into the market.
  • Global CD3 Antibodies Market, Dosage, Price, Sales & Clinical Trials Insight 2028 Report Highlights:
    Global CD3 Antibodies Market Opportunity: > USD 5 Billion By 2028
    CD3 Antibodies Clinical Trials Insight By Company, Country, Indication & Phase

TriSalus Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
星期二, 十一月 14, 2023
Oncology, Medical Devices, Health, Clinical Trials, Pharmaceutical, Biotechnology, Uveal melanoma, MDSC, Webcast, Sale, Interest, Liver disease, Pressure, Policy, ICI, Cancer, Commercial Operating System, Liver, Investment, Patient, PFS, Tumor microenvironment, Marketing, FACS, Neoplasm, TME, MD, SITC, Growth, Immunotherapy, Pharmaceutical industry

TriSalus Life Sciences Inc., (Nasdaq: TLSI), a publicly traded oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, today announced its financial results for the third quarter ended September 30, 2023, and provided a business update.

Key Points: 
  • TriSalus Life Sciences Inc., (Nasdaq: TLSI), a publicly traded oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, today announced its financial results for the third quarter ended September 30, 2023, and provided a business update.
  • “Today marks an important milestone for TriSalus as we host our first quarterly earnings call as a public company.
  • The seven percent improvement in the third quarter of 2023 is due to increased factory volumes and improved operations efficiency.
  • Operating losses are $18.5 million and $40.0 million, respectively, for the third quarter and nine months ended September 30, 2023.

Updated clinical safety and efficacy data for iOnctura's roginolisib presented at ESMO Immuno-Oncology Congress 2023

Retrieved on: 
星期五, 十二月 8, 2023
Uveal melanoma, Eye, Malignancy, Safety, Immune-related response criteria, Immune system, RECIST, Disease, Neoplasm, ESMO, Patient, Cancer, Survival, Overalls, NK, Vaccine, Medical imaging, Pharmaceutical industry

Roginolisib is in development for solid and hematologic malignancies including uveal melanoma, a rare cancer of the eye.

Key Points: 
  • Roginolisib is in development for solid and hematologic malignancies including uveal melanoma, a rare cancer of the eye.
  • Mass cytometry data showed treatment with roginolisib led to an increase in activated anti-cancer CD8+ T-cells and natural killer (NK) cells, increased interferon signalling and a decrease in cancer-promoting Regulatory T-cells.
  • Boosting of antitumoral immunity was observed in patients with long-term disease control after roginolisib treatment but not patients with progressive disease.
  • Catherine Pickering, Chief Executive Officer of iOnctura, said: "These safety and clinical efficacy data demonstrate iOnctura's progression of roginolisib.

Updated clinical safety and efficacy data for iOnctura's roginolisib presented at ESMO Immuno-Oncology Congress 2023

Retrieved on: 
星期五, 十二月 8, 2023
Uveal melanoma, Eye, Malignancy, Safety, Immune-related response criteria, Immune system, RECIST, Disease, Neoplasm, ESMO, Patient, Cancer, Survival, Overalls, NK, Vaccine, Medical imaging, Pharmaceutical industry

Roginolisib is in development for solid and hematologic malignancies including uveal melanoma, a rare cancer of the eye.

Key Points: 
  • Roginolisib is in development for solid and hematologic malignancies including uveal melanoma, a rare cancer of the eye.
  • Mass cytometry data showed treatment with roginolisib led to an increase in activated anti-cancer CD8+ T-cells and natural killer (NK) cells, increased interferon signalling and a decrease in cancer-promoting Regulatory T-cells.
  • Boosting of antitumoral immunity was observed in patients with long-term disease control after roginolisib treatment but not patients with progressive disease.
  • Catherine Pickering, Chief Executive Officer of iOnctura, said: "These safety and clinical efficacy data demonstrate iOnctura's progression of roginolisib.

Replimune Presents Updated Data on RP2 in Uveal Melanoma during Plenary Session at the 20th International Congress of the Society for Melanoma Research

Retrieved on: 
星期三, 十一月 8, 2023
Survival, FRCP, Research, Uveal melanoma, International Congress on Tuberculosis, Trae tha Truth, Nivolumab, University of Liverpool, Bachelor of Medicine, Bachelor of Surgery, DOR, Melanoma, Liver, Clatterbridge Cancer Centre NHS Foundation Trust, Doctor of Philosophy, Ipilimumab, Development, Lung, 8th Plenary Session of the Central Committee of the League of Communists of Serbia, Disease, Hypotension, Liver disease, Metastasis, RP2, Itch, Uvea, Immunotherapy, ORR, Chills, University, Society, Melanoma Research, Patient, Toxicity, Fatigue, Pharmaceutical industry, Fever

The data were presented by Dr. Joseph Sacco during a Plenary Session at the 20th International Congress of the Society for Melanoma Research in Philadelphia.

Key Points: 
  • The data were presented by Dr. Joseph Sacco during a Plenary Session at the 20th International Congress of the Society for Melanoma Research in Philadelphia.
  • The median duration of response (DOR) at the data cutoff was 11.47 months (range of 2.78 to 21.22 with responses ongoing).
  • RP2 was generally well tolerated both as monotherapy and in combination with nivolumab with no additive adverse events observed.
  • “These data from the trial cohort evaluating RP2 as monotherapy and in combination with nivolumab in metastatic uveal melanoma are highly promising,” said Robert Coffin, President and Chief Research & Development Officer at Replimune.

Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial

Retrieved on: 
星期三, 十一月 8, 2023
Patient, FDA, Research, Pharmacology, Uveal melanoma, Regenerative Medicine Advanced Therapy, Uterine cancer, NSCLC, International Congress on Tuberculosis, Corr, Cmax, Ovarian cancer, Nivolumab, Infrared spectroscopy correlation table, TCR, Appendix, CMC, Neurotoxicity, Lung, SD, DLT, Cytokine release syndrome, Melanoma, ORR, Cell therapy, Triple-negative breast cancer, CET, PRAME, Safety, CRS, Society, Melanoma Research, Diagnosis, Today, Cytopenia, BRAF, Pharmaceutical industry, Vaccine, Medical imaging, MD

The update is focused on IMA203 GEN1 in melanoma at the recently defined recommended Phase 2 dose (RP2D) and the first clinical data for IMA203CD8 GEN2.

Key Points: 
  • The update is focused on IMA203 GEN1 in melanoma at the recently defined recommended Phase 2 dose (RP2D) and the first clinical data for IMA203CD8 GEN2.
  • In line with previous results, IMA203 GEN1 monotherapy was well tolerated at total doses up to 10x109 TCR-T cells infused.
  • The presentation is available on Immatics’ website – covering the complete data set including Phase 1a, Phase 1b Cohort A and the deprioritized Cohort B (IMA203 GEN1 combined with nivolumab).
  • Discussions with FDA to align on patient populations, trial design and CMC aspects concerning the planned Phase 2 trial are ongoing.